74 results about "Fucosylation" patented technology

The invention discloses a production method of fucosylated oligosaccharide. The core of the method is as follows: the GDP-D-rhamnose is converted into the GDP-L-fucose by using the GDP-D-rhamnose-3, 5-epimerase; the GDP-D-rhamnose is obtained by converting the GDP-D-mannose-4, 6-dehydratase and the GDP-4-keto-6-deoxy D-mannose reductase by taking the GDP-D-mannose as a substrate, and the GDP-D-rhamnose is obtained by taking the GDP-D-mannose as a substrate. The invention relates to a method for producing a fucosylated oligosaccharide, which is characterized in that a GDP-D-mannose-4, 6-dehydratase, a GDP-4-keto-6-deoxyD-mannose reductase, a GDP-D-rhamnose-3, 5-epimerase and a fucosyltransferase are expressed in a genetically modified host cell, and the fucosylated oligosaccharide can be produced by the way mentioned above.

The present invention relates to inhibitors of protein fucosylation. More specifically, the present invention relates to carbocyclic compounds of formula (I) useful as inhibitors of protein fucosylation, or for the treatment of cancer, autoimmune diseases, infectious diseases, inflammatory diseases, or sickle cell diseases.

The invention belongs to the field of food, particularly relates to a nutritional composition and application thereof in improving immune disorder, and more particularly relates to application of the nutritional composition in preparing food for improving filial generation body inflammatory factor level disorder caused by maternal immune activation. The nutritional composition comprises essential active ingredients shown as the following (i) and (ii): (i) a neutral fucosylated breast milk oligosaccharide, (ii) a neutral non-fucosylated breast milk oligosaccharide; wherein the neutral fucosylated breast milk oligosaccharide at least comprises 2 '-fucosylated lactose, and the neutral non-fucosylated breast milk oligosaccharide at least comprises lactose-N-neotetraose; in addition, in the nutritional composition, the mass ratio of the lactose-N-neotetraose to the 2 '-fucosyllactose is 1: (1-8), and the 2'-fucosyllactose and the lactose-N-neotetraose can achieve a synergistic effect to regulate filial generation immunity.

The present invention relates to use of an enzyme that cleaves both alpha- and beta-1,4-glycosidic bonds and, more particularly, the present invention provides α-L-fucosidase which has α-1,4-glucosidase and β-1,4-galactosidase activities and thus is capable of producing glucose and / or galactose, which are monosaccharides, from non-fucosylated saccharides. The enzyme has transglycosylation activity and thus produces maltooligosaccharides having a higher degree of polymerization than maltooligosaccharides used as a substrate, thereby being applicable to the development of high-value-added new materials in the food industry.

The invention discloses a method, a system and equipment for evaluating the treatment effect of 2-Flurofuse on acute kidney injury. It is found for the first time that 2FF can treat acute kidney injury through the regulation effect on core fucosylation, an EMT process, an ERK signal channel and inflammation; the invention provides a method, a system and equipment for evaluating the treatment effect of 2FF on acute kidney injury on the basis of fucosylation and a method, a system and equipment for evaluating the treatment effect of 2FF on acute kidney injury on the basis of EMT for the field. The method, the system and the equipment are used for assisting clinicians in evaluating the treatment effect of patients with acute kidney injury.

This provides an inhibitor of protein fucosylation. [Solution] A method for inhibiting the fucosylation of a protein, or a fragment or derivative thereof, comprising contacting a eukaryotic cell or mammal with a specific carbocyclic compound or a salt thereof.

Compositions, systems, and kits are disclosed that comprise at least one immune checkpoint inhibitor and at least one immune cell type for adoptive cell therapy, wherein the at least one immune cell type has been fucosylated ex vivo (fuco-ACT). Also disclosed are methods of making and using the compositions, systems, and kits.

The present invention provides a fucosylated human milk oligosaccharide (HMO) for use in improving brain development and / or social emotional development in a subject wherein the fucosylated HMO is 3-fucosyllactose (3-FL), and wherein the subject is an infant, a young child, or a child.

The invention discloses application of 2-fluorofucose in preparation of a medicine for relieving acute kidney injury, and belongs to the technical field of biology. In-vitro cell experiments and animal experiments prove that 2-fluorofucose can inhibit core fucosylation, competitively inhibit the activity of fucosyltransferase, down-regulate the expression of FUT8 and reduce the core fucosylation level in kidney tissues and renal tubular epithelial cells; by inhibiting core fucosylation, effectively reversing EMT phenotypic transformation induced by hypoxia reoxygenation or ischemia reperfusion, up-regulating E-cadherin expression, down-regulating alpha-SMA and Snail expression and reducing cell migration ability, phosphorylation activation of an ERK pathway is remarkably inhibited, and downstream inflammatory factor release and cell injury signal transduction are blocked, so that the ERK pathway can be used for inhibiting ERK pathway phosphorylation activation. The invention provides application of 2-fluorofucose to preparation of a medicine for relieving acute kidney injury. The invention provides a new choice for treating acute kidney injury, has the outstanding advantages of remarkable curative effect, high safety and the like, and has a wide application prospect.

The invention relates to a nutritional composition comprising a probiotic and a mixture of human milk oligosaccharides (HMOs), wherein the probiotic is the Bifidobacterium bifidum (B. bifidum) R0071 strain (CNCM I-3426) or a strain having at least 97% average nucleotide identity with bacteria of said strain, and the mixture of HMOs comprises or consists essentially of 2'- fucosyllactose (2'-FL) and at least one additional HMO selected from an additional fucosylated HMO, a neutral core HMO, and / or a sialylated HMO. The invention also relates to the nutritional composition for use in supporting or improving gut health, immune system development and anti-inflammatory support, cognitive development, and / or emotional and behavioral development, in a subject.

The present invention provides for the use of recombinant Endo-S2 mutants (named Endo-S2 glycosynthases) that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sugar chain is added to a fucosylated or nonfucosylated GlcNAc-IgG acceptor. As such, the present invention allows for the synthesis and remodeling of therapeutic antibodies thereby providing for certain biological activities, such as, prolonged half-life time in vivo, less immunogenicity, enhanced in vivo activity, increased targeting ability, and / or ability to deliver a therapeutic agent.

This article describes antibodies or antigen-binding fragments that specifically bind to GPRC5D. Additionally, it includes monovalent antibodies or antigen-binding fragments that specifically bind to GPRC5D. The Fc regions of these antibodies contain K248E and T437R mutations (referred to as “RE mutations”) according to the EU numbering system. The described antibodies, when expressed in host cells lacking fucosylation capacity, exhibit enhanced antibody-dependent cytotoxicity (ADCC) and enhanced complement-dependent cytotoxicity (CDC).

The invention relates to a composition or a kit of parts comprising a probiotic and at least one human milk oligosaccharide (HMO), wherein the probiotic is the Bifidobacterium bifidum (B. bifidum) HA-132 strain (CNCM I-5898) or a strain having at least 97% average nucleotide identity with CNCM I-5898, and the at least one HMO is selected from a fucosylated HMO, a neutral core HMO, and a sialylated HMO, or is any mixture thereof, for use in supporting or improving cognitive development, emotional and behavioural development, immune system development and anti-inflammatory support, gut barrier function, and / or gut motility, in a subject. The invention further relates to a nutritional composition comprising a probiotic and at least one HMO, wherein the probiotic is the B. bifidum HA-132 strain (CNCM I-5898) or a strain having at least 97% average nucleotide identity with CNCM I-5898, and the at least one HMO is a sialyllactose.

The invention belongs to the field of food, and particularly relates to a nutritional composition and application thereof in improving sleep. The invention provides a nutritional composition. The nutritional composition comprises necessary active ingredients shown as (I) and (II) as follows: (I) casein phosphopeptides and (II) neutral non-fucosylated breast milk oligosaccharides, wherein the casein phosphopeptides are casein phosphopeptides, the casein phosphopeptides are casein phosphopeptides, the casein phosphopeptides are casein phosphopeptides, the neutral non-fucosylated breast milk oligosaccharide at least contains lactose-N-neotetraose, and in the nutritional composition, the mass ratio of the casein phosphopeptides to the lactose-N-neotetraose is 1: (0.1-15.0). According to the invention, the combination of the casein phosphopeptides and the lactose-N-neotetraose can effectively improve the sleep problem, even can improve the anxiety state caused by the sleep problem, and the casein phosphopeptides and the lactose-N-neotetraose also have a synergistic interaction effect.

The present invention relates to fucosylated mammalian milk oligosaccharides (MMO) for use in a method for the prevention and / or treatment of shipping fever in animals, more particularly in farm-bred animals or domesticated animals. More particularly, the present invention relates to fucosylated mammalian milk oligosaccharides (MMO) for use in a method for the prevention and / or treatment of shipping hot pneumonia and / or shipping hot diarrhea in animals, more particularly in farm-bred animals or domesticated animals.

The present invention relates to the technical field of functional enzymes, and in particular to an α-L-fucosidase mutant and an application thereof. The amino acid sequence of the mutant has at least 80% homology to the amino acid sequence of fucosidase SEQ ID NO: 1; the mutant has at least one characteristic sequence of the fucosidase, and the amino acid sequence of the fucosidase is modified, substituted, deleted or added with one or more amino acids to obtain the amino acid sequence of the mutant; the mutant has an amino acid sequence encoded by a nucleotide sequence shown in SEQ ID NO: 2 or its complementary sequence, or a sequence that is different from the nucleotide sequence of the nucleotide sequence shown in SEQ ID NO: 2 or its complementary sequence due to the degeneracy of the genetic code. The mutant provided by the present invention is beneficial to reducing the cost and reaction time in the catalytic reaction of fucosylated compound synthesis.

Disclosed are compositions, systems, and kits for adoptive cell therapy, comprising at least one immune checkpoint inhibitor and at least one immune cell type, wherein the at least one immune cell type is ex vivo fucosylated (fucoACT). Also disclosed are methods of making and using these compositions, systems, and kits.

The invention discloses a kit for detecting plasma IgG glycosylation level and a detection method thereof, and relates to the technical field of biological detection.Plasma IgG is specifically captured through protein A, four biotinylation lectins are combined, sialylation, galactosylation, fucosylation and mannosylation levels of IgG can be synchronously and quantitatively detected, a standardized ELISA system is established, and the kit is used for detecting the plasma IgG glycosylation level. Operation is easy and convenient, repeatability is good, and the problem that multi-dimensional simultaneous detection cannot be achieved in the prior art is solved. The kit is low in cost, does not need complex instruments, is suitable for large-scale clinical popularization, and fills the market blank of commercial IgG glycosylation ELISA kits. Clinical samples of colorectal cancer prove that patients and healthy people can be effectively distinguished, in-vitro risk assessment can be realized by combining a column diagram model, the detection efficiency is excellent, and the method can be expanded to be applied to assessment and monitoring of various tumor and inflammation related diseases, and has high clinical value.

The present invention provides a fucosylated human milk oligosaccharide (HMO) for use in improving brain development and / or vision development in a subject wherein: a) the fucosylated HMO is lactose-N-fucopentasaccharide-I (LNFP-I) and the subject is an infant of up to 12 months of age; and / or b) the fucosylated HMO is A-tetrasaccharide, wherein the individual is an infant, toddler or child.

The invention relates to a method for selective crystallization of 2′-FL from an aqueous solution comprising 2′-FL and one or more other fucosylated carbohydrates by adding acetic acid to the solution.

The present application belongs to the field of food, and particularly relates to a nutritional composition and its use for improving sleep. The present application provides a nutritional composition comprising essential active ingredients as shown in (I) and (II) below: (I) casein phosphopeptide, (II) neutral non-fucosylated human milk oligosaccharide; wherein the neutral non-fucosylated human milk oligosaccharide at least comprises lacto-N-neotetraose, and in the nutritional composition, the mass ratio of the casein phosphopeptide to the lacto-N-neotetraose is 1:(0.1-15.0). The present application proposes that the combination of casein phosphopeptide and lacto-N-neotetraose can effectively improve sleep problems, and even can improve the anxiety state caused by these sleep problems, and the two have a synergistic effect.

To provide a method for producing a recombinant antibody having a unique sugar chain spectrum from a genome-edited CHO host cell.SOLUTION: The method of the present invention is a method for editing fut8 genes in CHO cells suitable for suspension culturing in a serum free medium by TALEN technology, so that the edited CHO host cells can produce recombinant antibodies with unique glycan profiles. The unique glycan profile is characterized by having mainly non-fucosylated N-linked oligosaccharide chains, a low degree of heterogeneity of N-glycosylation, and uniform glycan chains. The antibodies prepared by the methods of the invention have increased ADCC activity and antibody stability.SELECTED DRAWING: Figure 10

The invention belongs to the field of food, and particularly relates to a nutritional composition and application thereof in improving intestinal microecology. The invention provides application of a nutritional composition in preparation of food for improving offspring intestinal microecological imbalance caused by maternal immune activation. The nutritional composition comprises essential active ingredients shown as the following (i) and (ii): (i) a neutral fucosylated breast milk oligosaccharide, (ii) a neutral non-fucosylated breast milk oligosaccharide; wherein the neutral fucosylated breast milk oligosaccharide at least comprises 2 '-fucosylated lactose, and the neutral non-fucosylated breast milk oligosaccharide at least comprises lactose-N-neotetraose; moreover, in the nutritional composition, the mass ratio of the lactose-N-neotetraose to the 2 '-fucosyllactose is 1: (1-9), and the 2'-fucosyllactose and the lactose-N-neotetraose can achieve a synergistic effect to improve the intestinal microecology of the offspring and provide benefits for the development of the nervous system of the offspring.

The present invention relates to a combination and nutritional composition comprising fucosylated human milk oligosaccharides, i.e., lactose-N-fucopentasaccharide-I (LNFP-I), as the most abundant human milk oligosaccharide in the combination or the nutritional composition, and Bifidobacterium longum subsp. Infantis (Bifidobacterium infantis). The combination and the nutritional composition are useful for treating, preventing and / or inhibiting the growth of intestinal pathogens, in particular in infants.

The invention belongs to the technical field of biology, and particularly relates to a method for simultaneously regulating and controlling multiple glycoforms of a cell expression product. The method comprises the step of adding a glycoform regulator in a cell culture process, wherein the glycoform regulator comprises one or more of galactose, manganese chloride, tris (hydroxymethyl) aminomethane, bis (2-hydroxyethyl) amino-tris (hydroxymethyl) methane and uridine. According to the method, antibody glycosylation modification can be effectively adjusted, particularly, the galactosylation rate, the mannosylation rate and the fucosylation rate can be regulated and controlled, on the basis, growth metabolism of cells, the expression quantity of antibodies and charge heterogeneity and purity are not affected, operation is easy, cost is low, and the method is suitable for regulating and controlling various similar biological drugs.

The present application relates to methods of producing a protein in fucosylated and afucosylated forms at a predetermined ratio by partially or completely inactivating GDP-keto-6-deoxymannose-3,5-epimerase, 4-reductae (GDP-L-fucose synthase, EC 1.1.1.271) and additionally by adjusting the presence or absence of fucose source during culturing.

Recombinant blood group antigen-binding adhesin (BabA) can be used in a composition to raise humoral immune response i.e. antibodies, that target conserved structural epitopes in the fucosylated blood group antigen Lewis b (Leb) antigen binding domain in the blood group antigen-binding adhesin (BabA). Such broadly Leb-blocking antibodies can reduce the gastric mucosal attachment of Helicobacter pylori (H. pylori) to human gastric mucosa. This approach can be used for preventing and / or alleviating gastric disease in a subject diagnosed with H. pylori infection, said gastric disease chosen from gastroesophageal reflux disease, chronic active gastritis, peptic ulcer diseases, gastric ulcer disease, gastric cancer gastritis and gastric cancer, in particular gastric cancer. It also becomes possible to identify subjects that carry BabA positive H. pylori infections and subjects that are at risk of developing severe gastric disease, such as peptic ulcer diseases, gastric ulcer disease, gastritis with metaplasia and gastric cancer.

This invention relates to a synthetic human milk oligosaccharide (HMO) mixture comprising 10-30 wt% acidic HMO and 70-90 wt% neutral HMO, wherein the neutral HMO comprises 75-95 wt% fucosylated HMO based on the weight of the neutral HMO, and to the use of the HMO mixture in the treatment and / or prevention of infection.

Disclosed are methods for treating a cancer and / or modulating immune CD4+ T cell mediated therapies comprising administering to a subject a fucose. In one aspect, disclosed herein are methods of modulating major histocompatibility complex II human lymphocyte antigen (HLA)-DRB 1 expression on the surface of a cell comprising contacting the cell with an agent that modulates the amount of fucosylation on the cell; wherein an increase in fucosylation increases surface expression of HLA-DRB 1; and wherein a decrease in fucosylation decreases the surface expression of HLA-DRB 1.

Provided herein are methods of modulating the levels of total afucosylated (TAF) glycoforms of a recombinant glycosylated protein produced by glycosylation-competent cells in a cell culture. In exemplary embodiments, the methods comprise maintaining the cell culture at an initial set point pH for an initial cell culture period. Related compositions comprising glycosylated proteins and TAF glycoforms thereof are also provided herein.